To address the risk of botulism in smoked fish, the Food and Drug Administration (FDA) undertook informal rulemaking to prescribe time–temperature–salinity processing limits for hot-smoked fish, including whitefish. The agency stated it relied on scientific literature and public health data (notably regarding Clostridium botulinum Type E) to support uniform, industry-wide requirements intended to ensure safety. After notice and comment, the FDA issued a final rule with specific processing parameters. Nova Scotia Food Products Corporation, a producer of smoked whitefish, was subsequently targeted by the United States in an enforcement action for noncompliance. As a defense, the company challenged the rule's validity under the APA, arguing that the FDA had withheld critical scientific studies and analyses during the comment period, relied on post-comment communications not placed in the docket, failed to grapple with industry comments asserting the rule would make compliant whitefish unsalable or economically infeasible, and issued only a conclusory statement of basis and purpose that did not address significant objections or alternatives (such as species-specific standards, refrigeration and labeling options, or feasibility concerns).
Did the FDA's smoked fish processing rule comply with APA § 553's procedural requirements when the agency did not disclose key scientific material during rulemaking, failed to respond to significant comments, and provided an inadequate statement of basis and purpose?
Under APA § 553, an agency engaged in informal rulemaking must: (1) provide notice of the proposed rule with sufficient detail to permit meaningful comment; (2) disclose the critical material on which it relies—especially scientific or technical data—so interested persons have a meaningful opportunity to comment; (3) consider and respond to significant comments that, if credited, would require a change in the rule; and (4) publish a statement of basis and purpose that explains the agency's reasoning on the major issues, enabling both public understanding and judicial review. An agency may not rely on undisclosed data or post-comment material as a basis for the final rule without affording an opportunity for comment, and a conclusory basis-and-purpose statement is inadequate.
The Second Circuit held that the FDA's rulemaking was procedurally deficient under the APA. Because the agency failed to disclose critical scientific data in time for meaningful comment, did not adequately respond to significant industry comments, and issued an insufficient statement of basis and purpose, the court set aside the rule to the extent challenged and remanded to the FDA for further proceedings consistent with the APA.
The court emphasized that meaningful participation in notice-and-comment rulemaking requires access to the technical bases underlying the proposal. The FDA referenced scientific studies and public health analyses but did not place those materials (or their essential substance) in the public docket during the comment period. This prevented affected parties from testing the agency's premises and deprived the agency of potentially valuable critique—contrary to the APA's purpose. The court relied on the principle that it is not consonant with the goals of rulemaking to promulgate rules on the basis of data known only to the agency or revealed too late for comment. Second, the court found the agency's failure to respond to significant comments unlawful. The record contained substantial industry submissions asserting that the prescribed processing parameters would render smoked whitefish commercially impracticable or unpalatable, and proposing alternatives (e.g., species-specific standards, refrigeration or labeling approaches). These were not peripheral gripes: if true, they would call for revisions or exceptions. Yet the FDA's final statement barely acknowledged, let alone reasoned through, these concerns. The APA's requirement to consider comments and provide a statement of basis and purpose obligates an agency to wrestle with such issues on the record. Third, the FDA relied on materials and communications received after the close of the comment period without reopening or otherwise exposing their substance for public evaluation. While informal rulemaking is flexible, the agency cannot insulate decisive post-comment inputs from scrutiny. Finally, the court deemed the statement of basis and purpose conclusory. It did not reveal the agency's reasoning regarding the scientific data, the feasibility objections, or the proposed alternatives, leaving the court unable to determine whether the agency took a hard look or acted arbitrarily. The cumulative effect of these procedural defects required setting aside the rule as promulgated.
Nova Scotia is a bedrock case for: (1) the duty to disclose critical scientific material to enable meaningful comment; (2) the obligation to respond to significant, outcome-determinative comments; and (3) the requirement to publish a statement of basis and purpose that addresses the major issues and explains the agency's reasoning. It strengthens judicial review by ensuring a transparent administrative record. After Vermont Yankee, courts continue to rely on Nova Scotia because its requirements flow from § 553's text and purpose, not from judicially invented add-ons. For law students, it frames exam analysis on adequacy of notice, comment responsiveness, record disclosure, and reasoned decision-making in informal rulemaking.
United States v. Nova Scotia Food Products Corp. ensures that informal rulemaking lives up to the APA's promise of participatory governance. When agencies rely on science to regulate, they must expose their critical data and reasoning to public scrutiny, engage with consequential objections, and explain their decisions with enough clarity to permit judicial review.